



GlaxoSmithKline Biologicals

Vaccines

More than 25 marketed vaccines

Vaccine	Indication	Target group
AmBrix	Hepatitis A + B	Children (>1 year) and adolescents (<16 years)
Boostrix	Diphtheria + Tetanus + Whooping cough (booster)	Children (>4 years), adolescents, adults
Boostrix Polio	DTP & Polio (booster)	Children (>4 years), adolescents, adults
Engerix B	Hepatitis B	Every age group
Fluarix / Alpharix / Influsplit	Influenza	Every age group (>6 months)
Havrix	Hepatitis A	Every age group (>1 year)
Hepatyrix	Hepatitis A + Typhoid	Adolescents (>15 years), adults, elderly
Hiberix	Haemophilus influenzae type b (Hib)	Children
Infanrix	Diphtheria + Tetanus + Whooping cough (DTPa)	Children
Infanrix Hib	DTPa + Hib	Children
Infanrix HepB	DTPa + Hepatitis B	Children
Infanrix Polio / Infanrix IPV	DTPa + Polio (IPV)	Children
Infanrix Polio Hib / Infanrix Quinta / Cinquerix	DTPa + Polio (IPV) + Hib	Children
Infanrix penta / Pediarix	DTPa + Polio (IPV) + Hepatitis B	Children
Infanrix hexa	DTPa + Polio (IPV) + Hepatitis B + Hib	Children
Mencevax A, AC, ACWY	Meningitis A, AC, ACW ₁₃₅ Y	Every age group (>2 years)
Polio Sabin (OPV)	Poliomyelitis	Children
Polio Salk (IPV)	Poliomyelitis (Only in combination with DTPa)	Children
Priorix	Measles + Mumps + Rubella	Children, adolescents, adults
Tanrix / Tevax	Tetanus	Every age group
Ditanrix / Tedivax pro adulto	Diphtheria + Tetanus	Every age group (>7 years)
Tritanrix HepB	DTPw + Hepatitis B	Children
Tritanrix HepB Hib	DTPw + Hepatitis B + Hib	Children
Twinrix	Hepatitis A + B	Every age group (>1 year)
Typherix	Typhoid	Every age group (>2 years)
Varilrix	Varicella	Children, adolescents, adults

For more information about the diseases that can be prevented by a GSK vaccine, please visit our medical website www.worldwidevaccines.com



Nearly 20 new products in development

The clinical studies (in man) include three phases:

- Phase I: Safety analysis
- Phase II: Immunogenicity analysis and « Proof of concept »
- Phase III: Efficacy analysis

Prophylactic vaccines	Target group	Phase
HIV	Adolescents and adults	I
Influenza (New delivery)	Adults and elderly	I
Pneumonia caused by Strepto. pneumoniae	Elderly	I
Tuberculosis	Children, adolescents, adults	I
Varicella Zoster	Elderly	I
Dengue fever	Children, adolescents, adults	I/II
Mononucleosis (Epstein-Bar virus)	Adolescents	II
Mosquirix (malaria)	Children	II
Meningitis caused by Neisseria Meningitidis	Children	II/III
Cervarix (cervical cancer caused by Human Papilloma Virus)	Female adolescents	III
Priorix Tetra (measles, mumps, rubella and varicella)	Children	III
Rotarix (gastro-enteritis caused by rotavirus)	Children	III
Streptorix (acute otitis media caused by S. pneumoniae)	Children	III
Simplirix (genital herpes)	Female adolescents	III
Therapeutic vaccines		
Breast cancer	Female adults	I
Melanoma (Mage 3)	Adults	II
Lung cancer (Mage 3)	Adults	II
Monoclonal antibodies		
Preventative for staphylococcal infections	Children	II

More vaccine approaches in preclinical research

In terms of vaccines in preclinical research (where no studies have yet been carried out in humans), the latest addition to the GSK Biologicals pipeline is a collaboration on a SARS vaccine, to prevent Severe Acute Respiratory Syndrome. Other viral projects include a paediatric vaccine against the respiratory syncytial virus (RSV), which is responsible for many babies under the age of twelve months being hospitalised, a new flu vaccine and a vaccine for adolescents against congenital diseases due to the cytomegalovirus. In terms of bacterial vaccines, a vaccine for children and adolescents against meningitis B caused by Neisseria Meningitidis and a vaccine for the elderly against pneumococcal pneumonia have made good progress. A vaccine against the Chlamydia Trachomatis bacteria, a cause of sterility in women, is being developed together with Corixa. Finally, a new therapeutic vaccine for the treatment of prostate cancer should enter clinical trials for the first time by the end of 2004.